Summary
| Full name | N6-glycinylcarbamoyladenosine |
| IUPAC name | 2-[[9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl]carbamoylamino]acetic acid |
| Short name | g6A |
| MODOMICS code new | 2000000065A |
| MODOMICS code | 65A |
| Synonyms |
2-(3-(9-((2R,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-6-yl)ureido)acetic acid
29902-55-4 |
| Nature of the modified residue | Natural |
| RNAMods code | ≡ |
| Residue unique ID | 114 |
| Found in RNA | Yes |
| Related nucleotides | 435 |
Chemical information
| Sum formula | C13H16N6O7 |
| Type of moiety | nucleoside |
| Degeneracy | not applicable |
| SMILES | OC(CNC(Nc1ncnc2c1nc[n]2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O)=O)=O |
| logP | -1.8922 |
| TPSA | 191.95 |
| Number of atoms | 26 |
| Number of Hydrogen Bond Acceptors 1 (HBA1) | 12 |
| Number of Hydrogen Bond Acceptors 2 (HBA2) | 13 |
| Number of Hydrogen Bond Donors (HBD) | 6 |
| PDB no exac match , link to the most similar ligand | AET |
| HMDB (Human Metabolome Database) no exact match, link to the most similar ligand | None |
| InChI | InChI=1S/C13H16N6O7/c20-2-5-8(23)9(24)12(26-5)19-4-17-7-10(15-3-16-11(7)19)18-13(25)14-1-6(21)22/h3-5,8-9,12,20,23-24H,1-2H2,(H,21,22)(H2,14,15,16,18,25)/t5-,8-,9-,12-/m1/s1 |
| InChIKey | AHESNRWOMYGILC-JJNLEZRASA-N |
| Search the molecule in external databases | ChEMBL ChemAgora ChEBI PubChem Compound Database Ligand Expo ChemSpider WIPO |
| PubChem CID | |
| PubChem SIDs |
* Chemical properties calculated with Open Babel - O'Boyle et al. Open Babel: An open chemical toolbox. J Cheminform 3, 33 (2011) (link)
Download Structures
| 2D | .png .mol .mol2 .sdf .pdb .smi |
| 3D | .mol .mol2 .sdf .pdb |
Tautomers
| Tautomers SMILES |
O=C(CNC(Nc1ncnc2c1ncn2C3OC(CO)C(O)C3O)=O)O tautomer #0
OC(C=NC(Nc1ncnc2c1ncn2C3OC(CO)C(O)C3O)=O)O tautomer #1 O=C(CNC(Nc1ncnc2c1ncn2C3OC(CO)C(O)C3O)=O)O tautomer #2 OC(C=NC(Nc1ncnc2c1ncn2C3OC(CO)C(O)C3O)=O)O tautomer #3 O=C(CNC(N=c1nc[nH]c2c1ncn2C3OC(CO)C(O)C3O)=O)O tautomer #4 OC(C=NC(N=c1nc[nH]c2c1ncn2C3OC(CO)C(O)C3O)=O)O tautomer #5 O=C(CNC(N=c1[nH]cnc2c1ncn2C3OC(CO)C(O)C3O)=O)O tautomer #6 OC(C=NC(N=c1[nH]cnc2c1ncn2C3OC(CO)C(O)C3O)=O)O tautomer #7 OC(=CNC(Nc1ncnc2c1ncn2C3OC(CO)C(O)C3O)=O)O tautomer #8 O=C(CN=C(Nc1ncnc2c1ncn2C3OC(CO)C(O)C3O)O)O tautomer #9 OC(=CNC(Nc1ncnc2c1ncn2C3OC(CO)C(O)C3O)=O)O tautomer #10 O=C(CN=C(Nc1ncnc2c1ncn2C3OC(CO)C(O)C3O)O)O tautomer #11 O=C(CNC(=Nc1ncnc2c1ncn2C3OC(CO)C(O)C3O)O)O tautomer #12 OC(C=NC(=Nc1ncnc2c1ncn2C3OC(CO)C(O)C3O)O)O tautomer #13 O=C(CNC(N=C1N=CN=C2C1N=CN2C3OC(CO)C(O)C3O)=O)O tautomer #14 OC(C=NC(N=C1N=CN=C2C1N=CN2C3OC(CO)C(O)C3O)=O)O tautomer #15 O=C(CNC(=Nc1ncnc2c1ncn2C3OC(CO)C(O)C3O)O)O tautomer #16 OC(C=NC(=Nc1ncnc2c1ncn2C3OC(CO)C(O)C3O)O)O tautomer #17 OC(=CNC(N=c1nc[nH]c2c1ncn2C3OC(CO)C(O)C3O)=O)O tautomer #18 O=C(CN=C(N=c1nc[nH]c2c1ncn2C3OC(CO)C(O)C3O)O)O tautomer #19 OC(=CNC(N=c1[nH]cnc2c1ncn2C3OC(CO)C(O)C3O)=O)O tautomer #20 O=C(CN=C(N=c1[nH]cnc2c1ncn2C3OC(CO)C(O)C3O)O)O tautomer #21 OC(=CN=C(Nc1ncnc2c1ncn2C3OC(CO)C(O)C3O)O)O tautomer #22 OC(=CN=C(Nc1ncnc2c1ncn2C3OC(CO)C(O)C3O)O)O tautomer #23 OC(=CNC(=Nc1ncnc2c1ncn2C3OC(CO)C(O)C3O)O)O tautomer #24 OC(=CNC(N=C1N=CN=C2C1N=CN2C3OC(CO)C(O)C3O)=O)O tautomer #25 O=C(CN=C(N=C1N=CN=C2C1N=CN2C3OC(CO)C(O)C3O)O)O tautomer #26 OC(=CNC(=Nc1ncnc2c1ncn2C3OC(CO)C(O)C3O)O)O tautomer #27 OC(=CN=C(N=c1nc[nH]c2c1ncn2C3OC(CO)C(O)C3O)O)O tautomer #28 OC(=CN=C(N=c1[nH]cnc2c1ncn2C3OC(CO)C(O)C3O)O)O tautomer #29 OC(=CN=C(N=C1N=CN=C2C1N=CN2C3OC(CO)C(O)C3O)O)O tautomer #30 |
| Tautomer image | Show Image |
Predicted CYP Metabolic Sites
| CYP3A4 | CYP2D6 | CYP2C9 |
|---|---|---|
|
|
|
* CYP Metabolic sites predicted with SMARTCyp. SMARTCyp is a method for prediction of which sites in a molecule that are most liable to metabolism by Cytochrome P450. It has been shown to be applicable to metabolism by the isoforms 1A2, 2A6, 2B6, 2C8, 2C19, 2E1, and 3A4 (CYP3A4), and specific models for the isoform 2C9 (CYP2C9) and isoform 2D6 (CYP2D6). CYP3A4, CYP2D6, and CYP2C9 are the three of the most important enzymes in drug metabolism since they are involved in the metabolism of more than half of the drugs used today. The three top-ranked atoms are highlighted. See: SmartCYP and SmartCYP - background; Patrik Rydberg, David E. Gloriam, Lars Olsen, The SMARTCyp cytochrome P450 metabolism prediction server, Bioinformatics, Volume 26, Issue 23, 1 December 2010, Pages 2988–2989 (link)
LC-MS Information
| Monoisotopic mass | 368.108 |
| Average mass | 368.302 |
| [M+H]+ | 369.1158 |
| Product ions | 237 |
| Normalized LC elution time * | not available |
| LC elution order/characteristics | not available |
* normalized to guanosine (G), measured with a RP C-18 column with acetonitrile/ammonium acetate as mobile phase.
Comments
g6A was isolated from bulk yeast tRNA
Chemical groups contained
| Type | Subtype |
|---|---|
| aminoacyl group | glycyl |
| other | carbamoyl |
Reactions producing N6-glycinylcarbamoyladenosine
| Name |
|---|
| A:g6A |
Publications
| Title | Authors | Journal | Details | ||
|---|---|---|---|---|---|
| The isolation and characterization of N-[9-(beta-D-ribofuranosyl)-purin-6-ylcarbamoyl]glycine from yeast transfer RNA. | Schweizer MP, McGrath K, Baczynskyj L... | Biochem Biophys Res Commun | [details] | 5503779 | - |
Last modification of this entry: Sept. 22, 2023